Answers are grounded in this paper and cite their sources.
Shows Isoacteoside improves muscle function in cancer cachexia, indicating therapeutic potential.
Cancer cachexia (CC), responsible for 40% of cancer-related deaths, lacks effective treatments. This study investigated Isoacteoside (ISO), a natural bioactive compound from the food-medicine plant Cistanche, against CC-induced muscle atrophy in cellular and animal models. ISO not only significantly improved muscle function (p<0.01), relative mass of gastrocnemius (+16.4 ± 1.6%), quadriceps (+31.92 ± 6.23%), tibialis anterior (+24.26 ± 4.22%), and ubiquitin ligases abnormal expression (p<0.01), but also enhanced mitochondrial quality control by reducing ROS (-53.76 ± 5.82%), improving mitochondrial membrane potential (+26.20 ± 9.63%), regulating pathways related to mitochondrial fusion, biogenesis, and autophagy. Critical target verification using molecular docking, molecular dynamics, cellular thermal shift assay, drug affinity responsive target stability, surface plasmon resonance confirmed ISO directly binds to Nrf2. Nrf2 knockout mice completely abolished ISO’s protective effects against CC-induced muscle atrophy. Our findings identify ISO as a novel therapeutic candidate addressing an unmet clinical need in CC.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: